Target engagement increased in a dose-dependent manner, with CD47 receptor occupancy ranging up to 100% at the highest doses evaluated. BRB-002 is a novel protein therapy that is being evaluated as an ...

“In 2024, we delivered strong progress and continued momentum for our clinical development program evaluating evorpacept as a ...

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...

ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker ...

including continued advancement of investigational CD47-blocker evorpacept and planned entry into the clinic of its novel EGFR-directed ADC clinical candidate ALX2004, and provide key business and ...

The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.

Cancer cells, when overexpressed with CD47, send a “don’t eat me” signal to macrophages, successfully shielding them from immune destruction. Similarly, tyrosine kinase inhibitors (TKIs) have ...

Cancer cells, when overexpressed with CD47, send a “don’t eat me” signal to macrophages, successfully shielding them from immune destruction. Similarly, tyrosine kinase inhibitors (TKIs) have ...

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing cancers.

Many solid tumors express the CD47 protein on their surface, which serves as a “don’t eat me” signal to the body’s immune system, allowing the tumor to evade detection. The antibody in this ATC ...